Jim Cramer sits down with Johnson & Johnson Chairman and CEO Alex Gorsky, who speaks to his company's partnership with Apple, deal to buy Auris Health and more. » Read More
By: Thomas Franck
Cannabis producer Canopy Growth was set to rally Friday after it reported third-quarter revenue rose 282 percent over the last year. » Read More |
While this year's flu season so far isn't quite as bad as last year's, activity is increasing and flu is now widespread, CDC officials said. » Read More |
Despite competition from other drugmakers, Pfizer has been able to maintain a significant share in the erectile dysfunction market thanks in part to launching its own generic version of the blue, diamond-shaped pill. » Read More |
The purchase gives J&J, one of the world's largest maker of health products, an entry into robotics and builds on the company's partnership with Alphabet's Verily.
The Food and Drug Administration said Monday it plans to modernize the agency's oversight of dietary supplements.
"These products, which are often sold on websites and social media platforms, have not been reviewed by the FDA and are not proven safe and effective to treat the diseases and health conditions they claim to treat," the FDA says.
The Trump administration's plan to force insurers to pass on drugmaker discounts to seniors at the pharmacy counter would upend the market and raise consumer premiums in the end, health insurance executives warned investors this week.
New York City's health department said restaurants in the city "are not permitted to add anything to food or drink that is not approved as safe to eat."
Sen. Ron Wyden, D-Ore., has stopped short of threatening to issue a subpoena to the drugmakers, indicating that participation at the hearing isn't entirely voluntary.
Alphabet's life science division Verily is building a tech-focused rehab facility to combat the opioid crisis. It wants to understand what works to treat addiction in the clinic and then track patient behavior when they get out to see what sticks.
Oscar's announcement credits Sankaran with being a "key member" of the executive team which helped the insurer through its restructuring and relisting in an IPO, after the financial crisis.
Smith refused to comment on a weekend report about Starboard taking a stake in the embattled pharmaceutical giant, which last month agreed to buy troubled cancer drug company Celgene in a cash-and-stock deal valued at $74 billion.
Pharmaceutical executives have already declined the Senate Finance Committee's invitation to testify about drug prices. Sen. Ron Wyden floated this possibility of issuing a subpoena forcing them to testify.
The hedge fund manager recommends that the drug company jump-start the business with new strategies.
Bank of America names Merck its top pick among the many U.S. pharmaceutical stocks thanks to the growing success of its key cancer drug.
Goldman Sachs' star beverage analyst was hoping to research the cannabis industry — that is, until she ran into the brokerage's firewall.
The rise could be due to the Trump administration's calls to repeal and replace the Affordable Care Act, the Harvard researchers say.
The size of the stake and plans that the activist hedge fund might have for its investment couldn't be immediately learned, according to Bloomberg.
Every year, over 100,000 Americans wait in "medical purgatory" for an organ transplant, and about 8,000 die on standby. Now researchers, doctors and policymakers are exploring innovative ways to increase the supply of organs to meet demand.
Get the best of CNBC in your inbox
Data also provided by 
